Understand the source comparison
GHRP-2 Acetate 40s Age Specific Protocol: Comparison
Dose per injection 200–300mcg 100–150mcg Pituitary sensitivity declines ~30% by age 45; lower per-dose concentration avoids receptor saturation Lower doses with higher frequency outperform high-dose protocols in 40+ cohorts Injection frequency 2x daily (mornin
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Dose per injection
- 200–300mcg
- 100–150mcg
- Pituitary sensitivity declines ~30% by age 45; lower per-dose concentration avoids receptor saturation
- Lower doses with higher frequency outperform high-dose protocols in 40+ cohorts
- Injection frequency
- 2x daily (morning, pre-sleep)
- 3x daily (morning, mid-afternoon, pre-sleep)
- Natural GH pulsatility decreases with age; three smaller pulses mimic youthful rhythm better than two large pulses
- Three daily pulses maintain elevated IGF-1 across waking and sleep cycles
- Fasting requirement
- 2 hours post-meal acceptable
- Minimum 3 hours post-carbohydrate meal
- Insulin sensitivity decreases after 40; elevated glucose blunts GH response more severely than in younger users
- Strict fasting adherence is non-negotiable for meaningful results
- Titration timeline
- Immediate 200mcg starting dose common
- Conservative 4-week escalation from 100mcg
- Older users experience higher cortisol response to abrupt GH elevation; gradual titration reduces side effects
- Slow titration prevents receptor downregulation and cortisol rebound
- Stacking contraindications
- Often stacked with other GHRPs or peptides
- Avoid stacking with additional GHRPs; CJC-1295 acceptable
- Receptor desensitisation risk compounds with age; single GHRP maintains pulsatility longer
- Monotherapy or conservative stacking only. Avoid multi-GHRP protocols